Registration to this Virtual Event is free of charge and gives you 180 days access. You will be sent details of how to access the event via email after registration.
For more information please click here.
 | Integration of High Throughput ‘Omic Platforms into Antibody Discovery
John Castle, University of Mainz
We use ‘omics technologies to identify and develop novel immune cell receptors. Our workflow harnesses cellular display, next-generation sequencing, mass-spec, bio data, biostatistics, and computational immunology from discovery to regulatory filing.
| |
 | Integration of High Throughput ‘Omic Platforms into Antibody Discovery
John Castle, The Institute for Translational Oncology and Immunology
We use ‘omics technologies to identify and develop novel immune cell receptors. Our workflow harnesses cellular display, next-generation sequencing, mass-spec, bio data, biostatistics, and computational immunology from discovery to regulatory filing.
| |
 | Integration of High Throughput ‘Omic Platforms into Antibody Discovery
John Castle, Agenus Switzerland Inc.
We use ‘omics technologies to identify and develop novel immune cell receptors. Our workflow harnesses cellular display, next-generation sequencing, mass-spec, bio data, biostatistics, and computational immunology from discovery to regulatory filing.
| |
| Advanced Targeting with Chimeric Antigen Receptors
Martin Pule, University College London
| |
 | Advanced Targeting with Chimeric Antigen Receptors
Martin Pule, UCL Autolus
| |
 | Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules Using Xpress CF™ Cell-Free Expression Technology
Roger Beerli, NBE Therapeutics
Antibody drug conjugates (ADCs) have recently been proven to be highly potent anti-tumor drugs, typically exceeding the efficacy of conventional monoclonal antibodies (mAbs). ADCs are currently produced by chemical conjugation of the small-molecule toxin to the mAb through lysine or cysteine side chains, leading to heterogeneous mixtures that present challenges with respect to analytical characterization and manufacturing. Furthermore, the individual components of these mixtures behave differently with respect to their pharmacokinetic, efficacy, and safety profiles. As a consequence, there is great interest in the further development of drug conjugation technologies, with a particular focus on site-specific payload conjugation. Here, we present an enzymatic conjugation platform called SMACTM (sortase-mediated antibody conjugation) technology that allows for efficient generation of homogeneous ADCs with pre-defined drug-to-antibody ratios. Data will be presented demonstrating that SMACTM technology is capable of producing homogeneous ADCs based on numerous toxic payloads, with high potencies for tumor cell killing in vitro and in vivo.
| |
 | Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules Using Xpress CF™ Cell-Free Expression Technology
Trevor Hallam, Sutro Biopharma Inc
Antibody drug conjugates (ADCs) have recently been proven to be highly potent anti-tumor drugs, typically exceeding the efficacy of conventional monoclonal antibodies (mAbs). ADCs are currently produced by chemical conjugation of the small-molecule toxin to the mAb through lysine or cysteine side chains, leading to heterogeneous mixtures that present challenges with respect to analytical characterization and manufacturing. Furthermore, the individual components of these mixtures behave differently with respect to their pharmacokinetic, efficacy, and safety profiles. As a consequence, there is great interest in the further development of drug conjugation technologies, with a particular focus on site-specific payload conjugation. Here, we present an enzymatic conjugation platform called SMACTM (sortase-mediated antibody conjugation) technology that allows for efficient generation of homogeneous ADCs with pre-defined drug-to-antibody ratios. Data will be presented demonstrating that SMACTM technology is capable of producing homogeneous ADCs based on numerous toxic payloads, with high potencies for tumor cell killing in vitro and in vivo.
| |
| Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules Using Xpress CF™ Cell-Free Expression Technology
Roger Beerli, NBE Therapeutics
| |
| Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules Using Xpress CF™ Cell-Free Expression Technology
Trevor Hallam, Sutro Biopharma Inc
| |
| OptiLinked FDCs: Fully Armed Antibody Fragment Drug Conjugates
Mahendra Deonarain, Imperial College London
| |
 | OptiLinked FDCs: Fully Armed Antibody Fragment Drug Conjugates
Mahendra Deonarain, Antikor Biopharma Ltd
| |
 | Roche's Approach to Discover, Design, Develop and Deliver Next Generation Protein Therapeutics
Stefan Weigand, F. Hoffmann-La Roche Ltd
My presentation will start with a problem statement regarding complexity of disease, pick up on diversity generation during binder generation, selection of best format (like bi-specifics, small-large molecule combos, brain-shuttle molecules) during LO phase, and end with showcasing that complex biologics can be produced for clinic with similar efficiency as IgGs - given the right set-up.
| |
 | Targeting ION Channels with Biologics
Tristan Vaughan, MedImmune Ltd
Successful approaches targeting ion channels will be described and a case study presented on the discovery of ion channel modulating antibodies.
| |
Back to the top
|
